Keyphrases
Head-and-neck Squamous Cell Carcinoma (HNSCC)
100%
Head-and-neck Cancer
68%
Cetuximab
56%
High-risk Human Papillomavirus (HR-HPV)
52%
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
47%
Overall Survival
43%
Phase II Trial
41%
Head-and-neck
36%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
34%
Recurrent or Metastatic
34%
Phase II Study
32%
Allogeneic Bone Marrow Transplantation
32%
Granulocyte Colony-stimulating Factor (G-CSF)
31%
Cisplatin
27%
Graft-versus-host Disease (GvHD)
27%
Locally Advanced
25%
Tumor
23%
Squamous Cell Carcinoma of Head
23%
Confidence Interval
23%
Randomized Phase II Trial
21%
Radiation Therapy
20%
Induction Chemotherapy
20%
Peripheral Blood Stem Cells
19%
Total Body Irradiation
19%
High-dose Chemotherapy
18%
Recurrent Metastatic
18%
Nab-paclitaxel
18%
Pembrolizumab
17%
Docetaxel
16%
Progression-free Survival
16%
Cyclophosphamide
16%
Clinical Outcomes
16%
Tumor Response
16%
Allogeneic Peripheral Blood Stem Cell Transplantation
15%
Solid Tumors
15%
Distant Metastasis
15%
Bone Marrow Transplantation
15%
Palbociclib
14%
Chemotherapy
14%
Neoadjuvant
14%
Metastatic Breast Cancer
14%
Soft Tissue Sarcoma
13%
Clinical Benefit
12%
Adjuvant Therapy
12%
Hazard Ratio
12%
Peripheral Blood Stem Cell Transplantation
11%
Transplant Recipients
11%
Nasopharyngeal Carcinoma
11%
Allogeneic
11%
Treatment-related Mortality
11%
Medicine and Dentistry
Head and Neck Squamous Cell Carcinoma
72%
Neoplasm
51%
Head and Neck Cancer
49%
Diseases
45%
Wart Virus
45%
Overall Survival
42%
Cetuximab
40%
Neck
33%
Oropharynx Squamous Cell Carcinoma
32%
Radiation Therapy
29%
Cisplatin
23%
Transplantation
23%
Squamous Cell Carcinoma
23%
Oropharynx Carcinoma
21%
Progression Free Survival
18%
Granulocyte Colony Stimulating Factor
17%
Pembrolizumab
17%
Paclitaxel
15%
Soft Tissue Sarcoma
15%
Induction Chemotherapy
14%
Malignant Neoplasm
14%
Immunotherapy
14%
Connective Tissue Cancer
13%
P16
13%
Recurrent Disease
13%
Hazard Ratio
13%
Cancer
13%
Distant Metastasis
12%
Neutrophil
12%
Adverse Event
12%
T Cell
12%
Biological Marker
12%
Arm
11%
Allogenic Bone Marrow Transplantation
11%
Autologous Stem Cell Transplantation
11%
Breast Cancer
11%
Adjuvant Therapy
11%
Granulocyte
11%
Whole Body Radiation
11%
Chronic Myelogenous Leukemia
10%
Metastatic Breast Cancer
10%
Metastatic Carcinoma
10%
Bone Cancer
10%
Disease Free Survival
10%
Allogeneic Peripheral Blood Stem Cell Transplantation
10%
Oncology
9%
Clinical Trial
9%
Conditioning
9%
Palbociclib
9%
Peripheral Blood Stem Cell
9%
Pharmacology, Toxicology and Pharmaceutical Science
Head and Neck Squamous Cell Carcinoma
68%
Cetuximab
51%
Overall Survival
39%
Neoplasm
39%
Head and Neck Cancer
34%
Diseases
32%
Chemotherapy
30%
Squamous Cell Carcinoma
27%
Progression Free Survival
23%
Cisplatin
23%
Human Papillomavirus
23%
Paclitaxel
20%
Solid Malignant Neoplasm
18%
Docetaxel
16%
Adverse Event
16%
Cyclophosphamide
16%
Palbociclib
14%
High Dose Chemotherapy
14%
Soft Tissue Sarcoma
13%
Malignant Neoplasm
12%
Acute Graft Versus Host Disease
12%
Remission
12%
Chemoradiation Therapy
11%
Oropharynx Squamous Cell Carcinoma
11%
Breast Cancer
11%
Pembrolizumab
11%
Metastatic Breast Cancer
10%
Growth Factor
10%
Neutropenia
10%
Immunotherapy
9%
Monotherapy
9%
Oral Mucositis
8%
Doxorubicin
8%
Biological Marker
8%
Organ Toxicity
7%
Placebo
7%
Dacarbazine
7%
Antitumor Activity
7%
Granulocyte Colony Stimulating Factor
7%
Epidermal Growth Factor Receptor
6%
Cyclin Dependent Kinase 4
6%
Methotrexate
6%
Disease Exacerbation
6%
Fluorouracil
6%
Graft Versus Host Reaction
6%
Nasopharynx Carcinoma
6%
Alpha Interferon
6%
Carboplatin
5%
Ciclosporin
5%
Granulocyte Macrophage Colony Stimulating Factor
5%
